Breast cancer is a multifactorial disease and driven by aberrant regulation of cell signaling
pathways due to the acquisition of genetic and epigenetic changes. An array of growth …

Breast cancer (BC) is the most common cancer in women worldwide, and has an
undeniable negative impact on public health. The advent of molecular biology and …

Following Milstein's discovery, the monoclonal antibodies (mAbs) became a basic tool for
biomedical science. In cancer field, since the first mAb was approved by the FDA a great …

Breast cancer is acknowledged as the second most prominent contributor to cancer-related
fatalities among females. The progression of breast cancer involves several sequential …

Simple Summary Early diagnosis and treatment of cancer is crucial for the survival of cancer
patients. Pathologists can use computational pathology techniques to make the diagnosis …

ErbB2 overexpression identifies a subclass of breast cancer as ErbB2-positive that is
frequently associated with poor prognosis. Current ErbB2-targeted therapies have …

Although resistance is its major obstacle in cancer therapy, trastuzumab is the most
successful agent in treating epidermal growth factor receptor 2 positive (HER2+) breast …

Purpose While HER2 testing is well established in directing appropriate treatment for breast
cancer, a small percentage of cases show equivocal results by immunohistochemistry (IHC) …

In an effort to discover a noninvasive method for predicting which cancer patients will benefit
from therapy targeting the EGFR and HER2 proteins, a large body of the research has been …

Objectives Monoclonal antibody-based of cancer therapy has been considered as one of the
most successful therapeutic strategies for both haematologic malignancies and solid …